Circulogene

Circulogene is excited to announce the exclusive commercial launch of LungLifeAI®

Labiotech.eu was founded in 2014 by two biotech engineers in response to the lack of digital media covering the European biotechnology industry.

Induction treatment in operable non-small cell lung cancer: the immune oncology era unfolds

Research indicates that positive PD-L1 detected by CIRCULOGENE liquid biopsy can have favorable outcomes for cancer patients

CIRCULOGENE’s liquid biopsy for PD-L1 status features in research presented at the recent AACR annual meeting

CIRCULOGENE’s blood-based, gene panel is central to research presented at last weekend’s Digestive Disease Week 2023

CIRCULOGENE is proud to announce the appointment of Robert “Bob” Gasparini, M.H.S., M.S., CG(ASCP), DLM(ASCP), to its Board of Directors.

CIRCULOGENE shares results of remarkable rectal cancer study
Identifying mismatch repair-deficient (MMRd) or microsatellite instability (MSI)

CIRCULOGENE presented plasma PD-L1 data at the American Society for Radiation Oncology (ASTRO) / American Society of Clinical Oncology (ASCO) Multidisciplinary Thoracic Cancers Symposium

Liquid Biopsy Company Laboratory Operations Are Growing in Pensacola

Issued patent recognizes CIRCULOGENE’s novel method of enriching cfDNA without DNA isolation, extraction or purification, enabling “in situ” genetic manipulation of biofluid samples.

Biological Fragmentation of Circulating Cell-free DNA Alters Genetic Representation

$1.5 Million grant to The Geneva Foundation will use CIRCULOGENE’s liquid biopsy to quickly ID and accurately quantify organ-specific injury markers for improved treatment and survival in severely wounded military and civilian personnel.